RTTNews BiotechQwen · 实盘不做把握 2/10不做原因:不是事件
北京时间·🕒 发布 22:56:58·⟳ 抓取 23:01:07 +4m09s·⚡ 决策 08-26 23:29:41 +28m34s·61.8 天前
BridgeBio已获批药物Acoramidis的ASCEND-ATTR上市后研究完成首例患者给药
ASCEND-ATTR是已获批药物Acoramidis的常规上市后承诺研究（Phase 3b/4），首例患者给药是最早期的操作性里程碑，不含任何新疗效数据、监管进展或商业增量。研究主要终点在36个月后，150人单臂开放设计对$15.7B市值无近期催化价值。自家案例库显示同一事件已于今日被处理并判定为'不做'。
📄 原文RTTNews Biotech↗ 原文
BridgeBio Doses First Participation In ASCENT-ATTR Study
BridgeBio Pharma, Inc. (BBIO) announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study de…
不做 BridgeBio Pharma（BBIO.US）
已获批药物Acoramidis的常规上市后研究（Phase 3b/4）首例给药，不含新疗效数据、监管进展或商业增量。150人/36个月终点的单臂开放研究对$15.7B市值无近期催化价值。股价零反应印证市场不视其为新信息。同一事件今日已被本系统处理并判定不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
BridgeBio已获批药物Acoramidis的ASCEND-ATTR上市后研究完成首例给药。按生物医药经验框架，事件仅将资产状态从'已获批'推进到'上市后研究启动'，不含新疗效数据或监管里程碑。150人、36个月终点的单臂开放研究对$15.7B市值无近期催化。股价当日零反应(-0.07%)印证市场不视其为新信息。结论：常规操作性公告，无交易edge。
🔎 新鲜度:最早出现 2026-08-26 · 扩散 low · price-in 风险 low ↗
消息传播链
- RTTNews发布BridgeBio ASCEND-ATTR首例给药公告，为当日常规新闻稿转发市场反应:BBIO当日-0.07%，零反应
反向证据
- 做多前查反向 · 来源 案例库+事件语义分析 · 日期 2026-08-26 · 影响 invalidates
该研究为36个月终点的单臂开放标签设计，主要终点为影像学指标改善，不直接改变处方行为或收入；自家案例库显示同一事件已被判定为不做
检索:ASCEND-ATTR clinical significance for BBIO valuation
先例如何影响了这次决策
对本次决策的影响:未改变决策；事件本身为常规操作性里程碑，无需先例校准
方向:无可用先例
涨幅量级:无
形态:无
工具调用 · 历史记录,结果未知(5 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
- web_search · 结果未知
- stock_quote · 结果未知
- search_case_library · 结果未知
原文全文
展开原文 · 2,016 字
BridgeBio Pharma, Inc. (BBIO) announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study designed to evaluate the long-term effects of Acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
The trial builds on earlier findings from the ATTRibute-CM CMR substudy, which suggested Acoramidis may not only slow disease progression but also improve cardiac structure and function, with evidence of amyloid regression in some patients.
Acoramidis is a selective, orally administered small molecules that stabilizes transthyretin (TTR) with near-complete (=90%) effectiveness. By preventing destabilization of the protein, the therapy may allow the body's natural clearance mechanisms to reduce amyloid deposits, enabling cardiac remodeling and functional recovery.
ASCENT-ATTR is a single-arm, open-label study enrolling about 150 participants with ATTR-CM. Patients will undergo annual cardiovascular magnetic resonance imaging and echocardiography over 36 months. The primary endpoint is improvement in left ventricular systolic function at Month 36, with secondary measures including cardiac structure, amyloid burden, biomarkers, and imaging assessments at Month 12 and 24.
ATTR-CM is a progressive and often fatal condition caused by amyloid deposits in the heart muscle. Current therapies aim to slow progression, but BridgeBio's program is designed to test whether long-term Acoramidis treatment can actively reverse disease damage and restore heart health.
BBIO has traded between $48.78 and $93.42 over the past year. The stock is currently trading at $80.24, down 0.20%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
The trial builds on earlier findings from the ATTRibute-CM CMR substudy, which suggested Acoramidis may not only slow disease progression but also improve cardiac structure and function, with evidence of amyloid regression in some patients.
Acoramidis is a selective, orally administered small molecules that stabilizes transthyretin (TTR) with near-complete (=90%) effectiveness. By preventing destabilization of the protein, the therapy may allow the body's natural clearance mechanisms to reduce amyloid deposits, enabling cardiac remodeling and functional recovery.
ASCENT-ATTR is a single-arm, open-label study enrolling about 150 participants with ATTR-CM. Patients will undergo annual cardiovascular magnetic resonance imaging and echocardiography over 36 months. The primary endpoint is improvement in left ventricular systolic function at Month 36, with secondary measures including cardiac structure, amyloid burden, biomarkers, and imaging assessments at Month 12 and 24.
ATTR-CM is a progressive and often fatal condition caused by amyloid deposits in the heart muscle. Current therapies aim to slow progression, but BridgeBio's program is designed to test whether long-term Acoramidis treatment can actively reverse disease damage and restore heart health.
BBIO has traded between $48.78 and $93.42 over the past year. The stock is currently trading at $80.24, down 0.20%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。